10x Genomics Inc Class A (TXG)

In Q2 2025, 10x Genomics reported an EPS of $0.28, exceeding the forecast of -$0.37, and revenue reached $173 million, surpassing expectations by 24.03%. Piper Sandler initiated coverage with a Neutral rating and a $15.00 price target. In Q3 2025, the company reported earnings of ($0.22) per share, beating consensus estimates of ($0.27), with revenue of $149.00 million, exceeding the consensus estimate of $142.50 million. 10x Genomics launched a new version of its Chromium Flex assay, designed for enhanced scalability and accessibility in large-scale research projects. The company announced a collaboration with Anthropic AI to integrate its analysis tools into Anthropic's Claude for Life Sciences platform. Barclays raised its price target to $22 from $17, maintaining an Overweight rating. Barclays further raised its price target to $22 from $17, BofA increased its target to $18 from $15, and Canaccord Genuity lifted its price target to $20. 10x Genomics announced preliminary Q4 2025 revenue of approximately $166.0 million, and full-year 2025 revenue, excluding patent litigation settlements, was approximately $598.7 million. 10x Genomics presented at the 44th Annual J.P. Morgan Healthcare Conference. The stock has shown impressive momentum, with a 59.8% price return over the past six months and a 30.24% increase over the past year, reaching a new 52-week high of $20.72 in January 2026.

Demand for consumables remains strong and generates recurring revenue, suggesting consistent demand. Sales of instruments have shown weakness due to cautious research spending and macroeconomic headwinds, indicating that instrument demand may be more susceptible to economic conditions and research funding cycles. Consumables demonstrate robust demand, while instrument sales are more sensitive to external funding environments.

10x Genomics, Inc. is a life science technology company based in California, specializing in genomic analysis solutions. It operates within the Healthcare sector, focusing on Healthcare Equipment & Supplies and Biotechnology: Laboratory Analytical Instruments. The company aims to accelerate biological discovery by providing scientists with tools for single-cell and spatial genomics. Its integrated solutions include instruments, consumables, and software for analyzing biological systems. The company's major product platforms include the Chromium, Visium, and Xenium platforms. The company's business model relies on a "razor-and-blade" approach, where instruments are the initial investment, and high-margin consumables generate recurring revenue.

10x Genomics generates its maximum revenue from the United States. The remaining revenue is derived from other regions, including the Americas (excluding the United States), Europe, the Middle East and Africa, China, and Asia-Pacific (excluding China).

10x Genomics has cultivated a strong brand reputation by enabling discoveries in various fields. Its integrated solutions are well-received, simplifying complex workflows and accelerating data generation. Continuous innovation across its platforms drives consumables revenue and market leadership. The partnership with Anthropic AI is expected to enhance market visibility and make single-cell and spatial analysis more accessible. No specific negative events significantly impacting the company's brand reputation in the past year were identified.

Ownership of 10x Genomics, Inc. is primarily concentrated among institutional investors, holding a significant majority. Major institutional owners include Vanguard Group Inc, ARK Investment Management LLC, and BlackRock, Inc. Insiders hold a smaller percentage of the stock, with Paladin Capital Management LLC noted as the largest individual shareholder. Public/Retail Investors hold a portion of the company's stock.